Introduction
============

Skin plays a significant role as a barrier that prevents water loss from the body, and is continually exposed to a variety of stimuli such as dryness, ultraviolet (UV) radiation, and chemical agents, all of which can damage both the skin surface and internal structures. Notably, the aging process is known to lead to upregulation of inflammation,[@b1-ccid-11-115]--[@b5-ccid-11-115] which occurs in response to the abovementioned stimuli and can result in disturbed turnover and roughness of skin related to decreased amounts of cellular components, including glycerolipids, natural moisturizing factors, and specific salts.[@b6-ccid-11-115],[@b7-ccid-11-115] Compared with internal organs, it is relatively easy to self-diagnose skin conditions such as dryness and wrinkles, and these conditions can have a huge impact on quality of life. As a result, skin dryness along with wrinkles represents one of the strongest areas in the skincare market,[@b8-ccid-11-115],[@b9-ccid-11-115] and there remains a huge demand for more effective ways to improve these conditions, despite numerous commercially available skincare products containing compounds such as hyaluronan, glucosylceramide, and collagen.[@b10-ccid-11-115]--[@b12-ccid-11-115]

Recently, a traditional Japanese cuisine called Washoku has been gathering interest internationally as well as in Japan, and has been certified as UNESCO's Intangible Cultural Heritage of Humanity owing to its outstanding principles -- namely, Washoku is an exceptionally well-balanced, respectful, and healthy way to produce and consume food.[@b13-ccid-11-115] Notably, the cuisine incorporates fermented foods and seasonings such as miso, soy source, and sake, which are commonly made with Koji -- the Japanese name for the fungus *Aspergillus*.[@b14-ccid-11-115] Industrially, *Aspergillus* has great value because of its prominent characteristics, such as the capability to produce useful protease and carbohydrase enzymes in large quantities. Therefore, many studies have been conducted worldwide on *Aspergillus* at the molecular level;[@b15-ccid-11-115],[@b16-ccid-11-115] however, there are only a limited number of reports on the health benefits of Koji and its metabolites. For instance, some of the active metabolites of *Aspergillus* or *Monascus* fungus include β-glucan for immune activation,[@b17-ccid-11-115] pyranonigrin A for antioxidation,[@b18-ccid-11-115] and 4-aminobutanoic acid for anti-stress effects.[@b19-ccid-11-115] Recently, we identified 14-dehydroergosterol (14-DHE, C~28~H~42~O) from *Aspergillus awamori* as a novel anti-inflammatory agent that induces regulatory T cells.[@b20-ccid-11-115],[@b21-ccid-11-115] 14-DHE was initially isolated as by-product in cultures of *Aspergillus niger*;[@b22-ccid-11-115] however, no biological activity was reported. In a previous study, injection of 14-DHE in mice significantly improved the clinical score and inflammatory response in a model of multiple sclerosis (experimental autoimmune encephalopathy).[@b20-ccid-11-115],[@b21-ccid-11-115] Additionally, 14-DHE suppressed the inflammatory phenotype in dendritic cells derived from human peripheral blood mononuclear cells in response to lipopolysaccharide and interferon-γ stimulation.[@b21-ccid-11-115] Furthermore, 14-DHE has been shown in vitro to protect keratinocytes against UVA radiation.[@b23-ccid-11-115]

The aim of the present study was to assess the effects of the oral administration of Koji extract containing 14-DHE in humans for the first time. To this end, the effects of 14--DHE-containing Koji extract on skin conditions were investigated by a randomized, double-blind, placebo-controlled, parallel-group experiment.

Materials and methods
=====================

This clinical trial was conducted in accordance with the principles of the Declaration of Helsinki, and followed Japanese Ministry of Health and Welfare Ordinance No. 28, Standards of Implementation of the Clinical Trial of a Pharmaceutical (March 27, Heisei 9). Thus, the trial obtained approval from the Ethics Committee of the Oriental Ueno Detection Center, General Incorporated Association Oriental Occupational Health Association Tokyo Branch. Informed consent was obtained in writing from each volunteer prior to enrollment in the study. The study received no specific grant or funding from external organizations.

Samples used in the trial
-------------------------

Two kinds of dietary samples in soft gelatin capsules were prepared for the study -- one was a placebo containing 200 mg rapeseed oil, and the other contained Koji extract comprising 0.1% 14-DHE dissolved in 200 mg rapeseed oil. The cultivated fungus body of *Aspergillus kawachii* was first extracted with 59% ethanol; then, rapeseed oil was added, and the oil fraction was collected as Koji extract. The concentration of 14-DHE in the Koji extract was determined by high-performance liquid chromatography (Shimadzu, Kyoto, Japan) using a C30-UG-5 column (Develosil, 10 mm × 250 mm; Nomura Chemical Co. Ltd., Aichi, Japan) with an acetonitrile--isopropanol (99:1) gradient as described by Ano et al.[@b21-ccid-11-115] The nutritional content of this sample was: energy, 1.8 kcal; lipids, 0.2 g; and carbohydrate, protein, alcohol, moisture, and ash, 0 g per capsule.

Subjects
--------

The study enrolled healthy Japanese female volunteers (aged 30--49 years) who were conscious of dry skin and fine wrinkles. The volunteers were recruited as follows ([Figure 1](#f1-ccid-11-115){ref-type="fig"}). First, 157 potential candidates were recruited from a sample of healthy female volunteers; 23 candidates were then excluded after screening on the basis of the exclusion criteria ([Table 1](#t1-ccid-11-115){ref-type="table"}). Lastly, 70 subjects from the remaining 134 were selected for the study after additional screening on the basis of low moisture content in the stratum corneum, high trans-epidermal water loss (TEWL) of their left cheek, grade 1--3 wrinkles by clinical diagnosis,[@b24-ccid-11-115] and high score related to moisture via a visual analog scale (VAS).

Study design
------------

The trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (no. UMIN000019758). The present study was designed as a randomized, double-blind, placebo-controlled, parallel-group trial, and was planned and conducted by TES Holdings Co., Ltd. Stratified block randomization was carried out to allocate the 70 study subjects to either the placebo group (n = 35) or the Koji group (n = 35). Specifically, the subjects were divided into two strata based on median age and median value of moisture in the stratum corneum and TEWL, and were then allocated to a group randomly with the use of computer-generated randomization numbers. Then, the trial was implemented in a double-blind and placebo-controlled manner. Both the data monitor and data analyst were blinded to the treatment assignment until the analyses were completed.

The two kinds of dietary capsules used in the study appeared identical. The personnel managing test foods in Kirin Company printed a mark (A or B) on the respective outer boxes enclosing the capsules, and delivered both the capsules and the identifying code table to the assignment manager, Akiyoshi Sawabe (Department of Food Science and Nutrition, Faculty of Agriculture, Kindai University). The assignment personnel confirmed that there were no differences in appearance between the two types of capsules, and then delivered them to the testing agency. The assignment list was not opened until the data had been entered and analyzed to ensure effective blinding.

The subjects ingested one capsule of either the placebo or Koji extract containing 14-DHE per day for 12 weeks. During the study, the 70 subjects were instructed to visit the hospital to have an evaluation of skin conditions by a medical doctor five times: weeks 0 (baseline), 4, 8, and 12 during the ingestion period, as well as week 16, corresponding to 4 weeks after the period of ingestion. As primary outcomes, skin moisture, TEWL, wrinkle grade, and skin conditions by VAS were evaluated. Before all measurements and skin examinations, subjects washed their face and then rested for 20 min in a waiting room kept under mild environmental conditions (room temperature, 21 ± 1°C; relative humidity, 50 ± 10%) in order to maintain homogeneous environmental and measurement conditions as far as possible. Subjects were instructed to comply with the following points during the trial: (1) avoid excessive eating and exercise; (2) have enough sleep; (3) use cosmetics and supplements in the same manner as they did before the trial; and (4) avoid outdoor activities under sunlight without protecting the measurement areas against UV radiation, such as by wearing clothes, a hat, a sunscreen, etc. The trial was carried out between November, 2015 and May, 2016 at the laboratories of TES Holdings Co., Ltd.

Subjective evaluations
----------------------

A VAS was used to subjectively evaluate how the subjects felt about their skin conditions. The objective score was obtained by a scaled length ranging from 0 to 100 mm (0, highest possible outcome; 100, lowest possible outcome). The following criteria were evaluated by the subjects through the VAS: overall skin condition, skin moisture, dryness of area around the eyes and mouth, crow's feet, skin smoothness, skin brightness, skin dullness, skin redness, skin spots, and skin elasticity and firmness.

Skin moisture
-------------

Skin moisture in the stratum corneum was measured using a Corneometer® CM825 instrument (Courage + Khazaka Electronic GmbH, Cologne, Germany) at three points: left cheek bone area, left mouth corner, and left forearm. Each value recorded in this test was taken as the average of three measurements. Note that the Corneometer outputs a score in arbitrary units (a.u.) because the instrument measures variation in electrostatic capacity, which depends on the moisture content of the stratum corneum.

Trans-epidermal water loss
--------------------------

TEWL is a suitable indicator to evaluate barrier function in the stratum corneum. TEWL scores (g/h/m^2^) were obtained by using a Tewameter® TM300 instrument (Courage + Khazaka Electric GmbH) at three points: left cheek bone area, left mouth corner, and left forearm.

Wrinkle evaluation
------------------

The study evaluated wrinkles -- defined as crevices extending into the dermal and subcutaneous layers[@b25-ccid-11-115] -- in the eye area by using the method of a skin replica at the inferolateral margin, 5 and 10 mm from the corner of the right eye. More specifically, a limited area of 10 mm × 10 mm in each replica sample was scanned by using an image analysis system ASA-03RXD (Asahibiomed Co., Ltd, Tokyo, Japan), which yielded the following parameters: area rate, volume rate, average depth (total wrinkle), average depth (maximum wrinkle), maximum depth (maximum wrinkle), maximum depth (total wrinkle), and number of wrinkles.

Statistical analysis
--------------------

The sample size was calculated under the assumption that TEWL values would be similar to those in previous reports.[@b26-ccid-11-115]--[@b28-ccid-11-115] It was calculated that, for a size of 29 in each group, statistical differences would be observed between the two groups, especially in TEWL values at 12 weeks as compared with the baseline period, assuming an average difference of 3.8 and a standard deviation of 5. Thus, it was considered sufficient to have 35 subjects per group for precise evaluation.

All data values were reported as the mean ± SE. Unpaired *t*-test was used to compare the analytical data (with baseline values subtracted) between the two groups (i.e., placebo and Koji extract). All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA) or SPSS 19 (IBM, Armonk, NY, USA). A *p*-value of \<0.05 was considered to be statistically significant, whereas a value between 0.05 and \<0.10 was considered to be a trend toward significance.

Results
=======

Baseline data
-------------

No adverse event related to the test supplement was reported throughout the course of the study. With respect to the number of subjects during the trial ([Figure 1](#f1-ccid-11-115){ref-type="fig"}), one subject in the placebo group left the trial just before it began for health reasons. In addition, data for two subjects in the placebo group were missing at 4 weeks and for one subject at 16 weeks due to private matters. In the Koji group, one subject left the trial after 8 weeks due to personal reasons. Thus, 68 subjects (age \[mean ± SD\] 41.1 ± 5.5 years) completed the trial (per-protocol set), and with a mean age of 40.9 ± 5.6 years (placebo, n = 34) and 41.3 ± 5.5 years (Koji, n = 34).

Questionnaire survey to determine subjective skin symptoms
----------------------------------------------------------

The volunteers evaluated their symptoms of skin conditions subjectively through the VAS system by responding to a questionnaire ([Table 2](#t2-ccid-11-115){ref-type="table"}). As a result, crow's feet at 8 weeks were significantly decreased in the Koji group as compared with the placebo group (*p* \< 0.05, [Table 2](#t2-ccid-11-115){ref-type="table"}). In addition, the Koji group showed a trend (*p* \< 0.10) toward better skin moisture (4 weeks), dryness around eyes/mouth (4 weeks), and overall skin condition (8 weeks) as compared with the placebo group. This subjective evaluation, which was scored by the volunteers themselves, was followed by an objective evaluation with instruments as described further.

Skin moisture in the stratum corneum and TEWL
---------------------------------------------

Skin moisture content in the stratum corneum was determined by a Corneometer ([Figure 2](#f2-ccid-11-115){ref-type="fig"}). No significant difference was observed between the two groups in the left cheek bone area or the left mouth corner. However, moisture (variance from the baseline score) in the left forearm was significantly improved at 4, 8, and 16 weeks in the Koji group as compared with placebo group (*p* \< 0.05).

The same three skin areas were subjected to TEWL evaluation ([Figure 3](#f3-ccid-11-115){ref-type="fig"}). No differences in values were observed between the two groups.

Evaluation of wrinkle with replica analysis
-------------------------------------------

Fine wrinkles were evaluated by measurements made at 5- and 10-mm distances from the corner from the right eye ([Table 3](#t3-ccid-11-115){ref-type="table"}). Statistical analysis did not detect convincing differences in most loci evaluated by the replica test, but a significant difference (*p* \< 0.05) in average wrinkle depth was found at a spot situated 10 mm from the corner of the eye at 12 weeks. This finding was inconsistent with the VAS data, which indicated that wrinkles improved in the Koji group.

Discussion
==========

The present study has revealed, for the first time, that Koji extract containing 14-DHE is beneficial for maintaining healthy skin conditions in humans. Briefly, ingestion of a supplement containing Koji extract for 12 weeks significantly improved the skin conditions of healthy females (aged 30--49 years) who were conscious of dry skin and wrinkles. On the other hand, there was no difference in the TEWL score, indicative of barrier function between the placebo and the Koji groups ([Figure 3](#f3-ccid-11-115){ref-type="fig"}). However, the TEWL score provides valuable information because the skin of the subjects in the Koji group was considered to be in a healthy condition at baseline. While skin moisture content was maintained or increased in the Koji group, the placebo group showed decreasing skin moisture content and their skin was considered to have become dry, which might lead to increased TEWL -- in other words, disruption of the barrier function of the skin. On the other hand, the study enrolled healthy female volunteers with a healthy skin barrier; as a result, the TEWL score did not change considerably from baseline and no difference was statistically detected between the two groups, which is reasonable and supports the examination design used in the study.

As compared with the placebo group, the Koji group showed a trend toward significance (*p* \< 0.10) in the VAS score of skin moisture or dryness around the eyes and mouth ([Table 2](#t2-ccid-11-115){ref-type="table"}), and a significant increase (*p* \< 0.05) in the skin moisture content of the forearm ([Figure 2](#f2-ccid-11-115){ref-type="fig"}). These consistent results indicate that the subjects confidently found an improvement in skin dryness. In general, only topical external applications to the forearm have an effect on the forearm. Here, however, ingestion of Koji extract had a moisturizing effect on forearm skin. Therefore, oral administration of 14-DHE might induce a systemic reaction and have an effect on the whole body. Further studies on the kinetics of 14-DHE in blood will be necessary to verify such an effect. This result can be rationalized because 14-DHE has been shown to protect cells against UVA radiation in vitro with increased transcription of genes involved in ceramide formation from sphingolipids/cholesterol-rich lipid rafts,[@b6-ccid-11-115] whereas excess inflammation is known to have an unfavorable impact on the skin -- for example, by reducing natural moisturizing factors and skin turnover.[@b7-ccid-11-115] Indeed, ingestion of anti-inflammatory substances from aloe vera has been reported to increase skin moisture.[@b29-ccid-11-115],[@b30-ccid-11-115] These observations reasonably lead us to consider that the anti-inflammatory effect of 14-DHE contributed to the significant improvement in skin moisture in the present study. Furthermore, as an anti-inflammatory substance, 14-DHE might improve age-related phenotypes other than skin conditions.[@b31-ccid-11-115]--[@b35-ccid-11-115]

Previously, glucosylceramide from *A. kawachii* was shown to have a beneficial effect on skin conditions.[@b36-ccid-11-115] However, an analysis of Koji extract did not detect the presence of glucosylceramide (data not shown); thus, it is likely that 14-DHE contributed to the improvements in skin conditions observed in this study. Although we did not elucidate the pharmacokinetics of 14-DHE, it seems reasonable to consider that the skin moisture content was improved owing to the anti-inflammation competence of 14-DHE in the Koji extract.

It is necessary to consider why the subjects in the Koji group showed a tendency toward better skin conditions ([Table 2](#t2-ccid-11-115){ref-type="table"}). Taking the result of the VAS questions into consideration, the improvement in score might be attributed to an improved feeling, not only on skin dryness but also on wrinkles. Indeed, the VAS score on crow's feet was significantly improved in the Koji group after 8 weeks of consumption ([Table 2](#t2-ccid-11-115){ref-type="table"}). However, inconsistent with the VAS results, the replica analysis did not show a convincing improvement in wrinkles ([Table 3](#t3-ccid-11-115){ref-type="table"}). The results showed that there are substantial difficulties in evaluating improvements in wrinkles by replica analysis, which might be due to the following two reasons: (1) the replica analysis was not powerful enough to detect the depth and width of wrinkles as compared with a contactless optical tomographic imaging method; and/or (2) measurements of the roughness and wrinkles of the skin surface may have been smoothed because two replica samples are collected.[@b37-ccid-11-115] Thus, it is necessary to further examine wrinkle conditions in a different manner, such as through an optical tomographic imaging method. Nevertheless, it was noted that only a single item in the replica analysis showed a worse score from the baseline in the Koji group ([Table 3](#t3-ccid-11-115){ref-type="table"}); a possible reason for this was skin irritation, which one of the subjects reported due to the replica patch. In future studies, exclusion of subjects with sensitive skin might provide a more stable replica evaluation of fine wrinkles.

It is important to consider the limitations of this study including the sample size (n = 35 per group), which might not be sufficient to assert a definitive conclusion as compared with previous studies.[@b26-ccid-11-115]--[@b28-ccid-11-115] In other words, further studies should be carried out to statistically validate the effects of the Koji extract. However, it was important to set solid criteria for the subjects to conduct a convincing trial. In general, women pay more attention to their skin conditions as compared with men, and women younger than 30 years are less conscious of skin troubles, such as dry skin and wrinkles, than women aged 30 years or older, who were considered suitable for this trial. On the other hand, it was considered unreasonable to enroll females older than 50 years, who are more likely to have deteriorating skin conditions due to menopause. Nonetheless, there are many healthy people with skin concerns such as dryness even between the ages of 30 and 50 years, and the effect of Koji extract on improving skin moisture content is expected to be widely applicable to people in general.

In summary, this study has given new insight into the health benefits of metabolites in Koji, which is used in the traditional Japanese cuisine Washoku that is considered to provide a nutritionally balanced diet. It might be possible that Japanese people have so far received these benefits and have also noted the impressive competence of Koji. Together with this report, further studies on Koji are expected to lead to a healthier life for people.
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![Summary flow chart of the study design.\
**Notes:** "Missing data" means a subject was absent for the evaluation.\
**Abbreviation:** w, week.](ccid-11-115Fig1){#f1-ccid-11-115}

![Skin moisture was measured with a Corneometer® in the placebo and Koji groups on the (**A**) cheek, (**B**) corner of the mouth, and (**C**) forearm.\
**Notes:** Subtracted values against the baseline (the initial condition) were shown as means ± SE. \**p* \< 0.05 versus placebo.\
**Abbreviation:** a.u., arbitrary units.](ccid-11-115Fig2){#f2-ccid-11-115}

![TEWL measurement with Tewameter® TM300 throughout the course of the trial in the placebo and Koji groups on the (**A**) cheek, (**B**) corner of the mouth, and (**C**) forearm.\
**Note:** Subtracted values against the baseline (the initial condition) were shown as means ± SE.\
**Abbreviation:** TEWL, trans-epidermal water loss.](ccid-11-115Fig3){#f3-ccid-11-115}

###### 

Exclusion criteria in the study

  ------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\)    Individuals who have some diseases requiring drug therapy.
  2\)    Individuals who consecutively receive medications for treatment of disease in the last 1 month, except cold or medical history of pollinosis.
  3\)    Individuals who have severe disease histories in the liver, kidney, heart, lung, blood, or other tissues.
  4\)    Individuals who have a comorbidity or disease history in respiratory system
  5\)    Systolic and diastolic blood pressures \>160 mmHg and \>100 mmHg, respectively.
  6\)    Individuals who have donated \>200 or \>400 mL of blood in the last 1 or 3 months.
  7\)    Individuals who have severe anemia.
  8\)    Individuals who could have some allergy to the test diet, or who could have severe allergy to foods or medicines.
  9\)    Individuals who are pregnant, breastfeeding, or planning to conceive in the near future.
  10\)   Individuals who are alcoholic or have mental disorders.
  11\)   Individuals who have a smoking habit.
  12\)   Individuals who have irregular defecation, e.g., severe constipation, loose stool, and diarrhea.
  13\)   Individuals who could change their lifestyle during the study, e.g., changing their work shift from day to night, traveling for a long time.
  14\)   Individuals whose skin is extremely sensitive, or who have chronic ruddy complexion, outstanding pores, or freckles.
  15\)   Individuals who have some skin diseases such as atopic dermatitis.
  16\)   Individuals who could have a seasonal allergy such as pollen allergy.
  17\)   Individuals who have severe menopausal symptoms.
  18\)   Individuals who have severe poor circulation.
  19\)   Individuals who cannot care for their skin enough.
  20\)   Individuals who are willing to get sunburn, spend long durations outdoors, e.g., undertaking outdoor sports such as skiing and snowboarding, during the study.
  21\)   Individuals who habitually intake functional foods, healthy foods, or supplements that could get skin condition better in the last 3 months, or who are planning to ingest them during the study.
  22\)   Individuals who habitually use cosmetics or foods made of Koji.
  23\)   Individuals who routinely use pharmaceuticals that could have improved skin conditions in the last 3 months.
  24\)   Individuals who use cosmetics that could have strong effects on skin moisture or wrinkles.
  25\)   Individuals who underwent a surgery on their faces or arms in the last 6 months.
  26\)   Individuals who participated in other clinical trials in the last 3 months.
  27\)   Individuals who, and/or whose family, work for a company manufacturing or selling health foods, functional foods, or cosmetics.
  28\)   Individuals who are judged unsuitable for this study by the investigator for other reasons.
  ------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Changes in the subjective evaluation of skin conditions with time following ingestion of Koji extract and placebo

                                                     Questionnaire survey (subtracted values)                                                                                                                                                                                      
  ------------------------------------------- ------ ------------------------------------------ -------------- --------------------------------------------------- -------------- --------------------------------------------------- -------------- -------------- -------------- -------
  Overall skin condition                      Koji   34                                         −0.49 ± 0.29   0.760                                               −0.63 ± 0.23   0.086                                               −1.06 ± 0.22   0.137          −0.87 ± 0.19   0.183
  Placebo                                     34     −0.37 ± 0.27                                              −0.01 ± 0.27                                                       −0.44 ± 0.35                                                       −0.36 ± 0.33                  
  Skin moisture                               Koji   34                                         −1.14 ± 0.25   0.068                                               −0.82 ± 0.29   0.436                                               −1.33 ± 0.23   0.388          −1.11 ± 0.21   0.427
  Placebo                                     34     −0.48 ± 0.25                                              −0.50 ± 0.29                                                       −0.99 ± 0.32                                                       −0.83 ± 0.29                  
  Dryness of area around the eyes and mouth   Koji   34                                         −1.20 ± 0.35   0.050                                               −0.95 ± 0.30   0.209                                               −1.09 ± 0.29   0.821          −0.87 ± 0.27   0.706
  Placebo                                     34     −0.28 ± 0.29                                              −0.43 ± 0.29                                                       −0.98 ± 0.36                                                       −1.04 ± 0.37                  
  Crow's feet                                 Koji   34                                         −1.06 ± 0.21   0.105                                               −1.38 ± 0.27   0.016[\*](#tfn1-ccid-11-115){ref-type="table-fn"}   −1.59 ± 0.26   0.152          −1.03 ± 0.20   0.455
  Placebo                                     34     −0.50 ± 0.27                                              −0.47 ± 0.25                                                       −0.97 ± 0.34                                                       −0.75 ± 0.32                  
  Skin smoothness                             Koji   34                                         −1.17 ± 0.33   0.184                                               −0.92 ± 0.24   0.388                                               −1.08 ± 0.34   0.942          −1.13 ± 0.28   0.616
  Placebo                                     34     −0.62 ± 0.23                                              −0.60 ± 0.28                                                       −1.12 ± 0.34                                                       −0.92 ± 0.29                  
  Skin brightness                             Koji   34                                         −0.64 ± 0.22   0.816                                               −0.71 ± 0.20   0.356                                               −1.17 ± 0.23   0.510          −0.96 ± 0.20   0.199
  Placebo                                     34     −0.72 ± 0.26                                              −0.42 ± 0.24                                                       −0.93 ± 0.28                                                       −0.57 ± 0.23                  
  Skin dullness                               Koji   34                                         −0.91 ± 0.20   0.905                                               −1.11 ± 0.16   0.135                                               −1.53 ± 0.22   0.221          −0.98 ± 0.20   0.587
  Placebo                                     34     −0.96 ± 0.32                                              −0.70 ± 0.22                                                       −1.10 ± 0.27                                                       −0.83 ± 0.20                  
  Skin redness                                Koji   34                                         0.40 ± 0.24    0.021[\*](#tfn1-ccid-11-115){ref-type="table-fn"}   0.48 ± 0.29    0.115                                               0.14 ± 0.36    0.909          0.49 ± 0.32    0.229
  Placebo                                     34     −0.35 ± 0.20                                              −0.11 ± 0.23                                                       0.09 ± 0.24                                                        −0.02 ± 0.27                  
  Skin spots                                  Koji   34                                         −0.38 ± 0.19   0.226                                               −1.03 ± 0.25   0.226                                               −0.94 ± 0.27   0.832          −1.16 ± 0.29   0.112
  Placebo                                     34     −0.81 ± 0.30                                              −0.57 ± 0.28                                                       −0.86 ± 0.28                                                       −0.51 ± 0.29                  
  Skin elasticity and firmness                Koji   34                                         −0.69 ± 0.24   0.929                                               −0.79 ± 0.26   0.327                                               −1.28 ± 0.27   0.680          −1.17 ± 0.23   0.201
  Placebo                                     34     −0.66 ± 0.27                                              −0.42 ± 0.27                                                       −1.11 ± 0.30                                                       −0.69 ± 0.29                  

**Note:**

*p* \< 0.05 (unpaired Student's *t*-test between the two groups).

###### 

Changes in wrinkles with time following treatment in the Koji and placebo groups

                                                                                                Wrinkles evaluation (subtracted values)                                                                                                         
  ------------------------------- ----------------- ----------------- ------ ------------------ ----------------------------------------- ----------------- ------------------ ----------------- ---------------- ----------- ----------------- -------
  Area rate                       μm^2^/mm^2^/100   5 mm              Koji   34                 0.072 ± 0.109                             0.535             0.084 ± 0.077      0.765             0.301 ± 0.087    0.574       0.134 ± 0.138     0.797
  Placebo                         34                0.171 ± 0.114            0.048 ± 0.096                                                0.211 ± 0.131                        0.188 ± 0.154                                                    
  Volume rate                     μm^3^/mm^2^/100                     Koji   34                 1.87 ± 1.99                               0.553             0.95 ± 1.24        0.865             5.89 ± 1.92      0.730       2.19 ± 2.44       0.460
  Placebo                         34                3.61 ± 2.13              1.37 ± 2.15                                                  4.64 ± 3.03                          5.17 ± 3.16                                                      
  Average depth (total wrinkle)   μm                                  Koji   34                 0.551 ± 0.999                             0.652             −0.041 ± 0.925     0.307             3.124 ± 1.305    0.669       1.775 ± 1.329     0.288
  Placebo                         34                1.234 ± 1.136            1.665 ± 1.384                                                2.323 ± 1.330                        3.709 ± 1.221                                                    
  Average depth (max wrinkle)     μm                                  Koji   34                 0.675 ± 1.891                             0.794             −0.265 ± 1.567     0.468             3.636 ± 1.925    0.914       1.919 ± 2.038     0.107
  Placebo                         34                1.378 ± 1.885            1.588 ± 2.004                                                3.940 ± 2.021                        6.750 ± 2.137                                                    
  Max depth (max wrinkle)         μm                                  Koji   34                 25.365 ± 14.635                           0.776             −16.191 ± 10.780   0.876             9.040 ± 11.749   0.805       15.867 ± 13.850   0.226
  Placebo                         34                18.872 ± 17.518          −13.511 ± 13.274                                             13.749 ± 14.984                      42.092 ± 16.424                                                  
  Number of wrinkles              N/mm                                Koji   34                 −0.003 ± 0.010                            0.761             0.006 ± 0.009      0.327             0.007 ± 0.010    0.860       0.006 ± 0.013     0.559
  Placebo                         34                0.001 ± 0.010            −0.007 ± 0.009                                               0.005 ± 0.009                        −0.004 ± 0.011                                                   
  Area rate                       μm^2^/mm^2^/100   10 mm             Koji   34                 0.050 ± 0.084                             0.989             0.064 ± 0.080      0.617             0.254 ± 0.080    0.410       0.246 ± 0.113     0.284
  Placebo                         34                0.052 ± 0.084            0.136 ± 0.121                                                0.160 ± 0.082                        0.095 ± 0.080                                                    
  Volume rate                     μm^3^/mm^2^/100                     Koji   34                 1.01 ± 1.23                               0.890             0.89 ± 1.13        0.530             4.34 ± 1.40      0.290       3.70 ± 1.72       0.323
  Placebo                         34                0.77 ± 1.23              2.40 ± 2.13                                                  2.34 ± 1.21                          1.58 ± 1.24                                                      
  Average depth (total wrinkle)   μm                                  Koji   34                 0.665 ± 0.725                             0.540             0.790 ± 1.062      0.726             3.214 ± 0.978    0.035^\*^   2.147 ± 1.116     0.371
  Placebo                         34                0.027 ± 0.739            1.376 ± 1.290                                                0.378 ± 0.882                        0.822 ± 0.951                                                    
  Max depth (total wrinkle)       μm                                  Koji   34                 −1.388 ± 6.861                            0.947             −9.655 ± 7.375     0.395             2.577 ± 9.238    0.958       −2.691 ± 6.840    0.510
  Placebo                         34                −0.707 ± 7.562           −0.426 ± 7.884                                               3.220 ± 8.099                        4.344 ± 8.147                                                    
  Number of wrinkles              N/mm                                Koji   34                 −0.006 ± 0.011                            0.745             0.003 ± 0.011      0.939             0.012 ± 0.012    0.614       0.013 ± 0.013     0.468
  Placebo                         34                −0.001 ± 0.011           0.002 ± 0.009                                                0.020 ± 0.011                        0.000 ± 0.011                                                    

**Note:** A significant difference (*p* \< 0.05) in average wrinkle depth was found at the spot 10-mm from the corner of the eye at 12 weeks, (unpaired Student's *t*-test between the two groups).
